Development of a Recombinant Adeno-Associated Virus Vector for Human T Lymphocyte- and Natural Killer Cell-Targeted Gene Therapy.
A CD7-targeted rAAV vector featuring a nanobody-fused hybrid capsid derived from a rationally selected chimeric combination of AAV6 and AAV9 establishes an integrated capsid-genome design framework for targeting human T and NK cells, notoriously challenging immune cell populations for gene therapy, and provides a versa...